J&J MedTech Bolsters AFib Treatment Capabilities with Latest Platform Enhancements
Published: 05 Feb 2026
Author: Precedence Research
Johnson & Johnson MedTech has described the complete commercialization of its NuVision Nav ultrasound catheter, together with the release of the enhanced Varipulse Plus platform. This is a major push in the portfolio of the company in the sphere of electrophysiology (EP). These releases highlight how the company is still committed to changing the treatment of atrial fibrillation (AFIB) with precision-based, imaging-based, and workflow-based technologies. Johnson and Johnson MedTech would be the first to take advantage of real-time imaging, advanced mapping, and pulsed field ablation (PFA). They further boost the procedural confidence, uniformity, and safety of physicians everywhere.
The Varipulse Plus system will be the further development of the Varipulse PFA technology by the company. Automated irrigation flow is the new feature of the updated system. That will facilitate the simplification of procedures and strengthen the safety profile that the platform has established. Johnson & Johnson MedTech also focused on the fact that Varipulse is the first PFA technology to facilitate ablation and mapping in the same integrated workflow with the CARTO(r) 3 electroanatomic mapping system. Integration enables electrophysiologists to view complex cardiac anatomy in 3-D and provides more controlled and reproducible energy, which ultimately benefits patients with AFib.
The company observed that NuVision Nav is intended to reduce the amount of catheter operating and simplify navigation that is especially useful in difficult anatomy or repeat operations. The catheter provides the capability to visualize in real-time, at high-resolution. They are directly in the mapping environment, which underpins a more imaging-driven form of electrophysiology. Furthermore, with the growing attention of healthcare systems to efficiency, safety, and standardization, the company feels that its integrated EP solutions are well-positioned to help clinicians and patients in the long term.
Executive Statement
Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson, said
“Evidence-based innovation is the foundation of how we advance arrhythmia care. The data and technology updates we are sharing at AF Symposium demonstrate how we are continuously strengthening our electrophysiology portfolio. These technology advancements and upcoming iterations are built on our scientific foundation and will continue raising the bar for AFib ablation.”